Cytokinetics Inc

NASDAQ:CYTK  
17.16
+0.57 (+3.44%)
Regulatory, Earnings Announcements

Cytokinetics Announces Results From Galactic-Hf Trial

Published: 11/13/2020 17:08 GMT
Cytokinetics Inc (CYTK) - Cytokinetics Announces Results From Galactic-hf Presented at Late Breaking Clinical Trial Session at the American Heart Association Scientific Sessions and Published in the New England Journal of Medicine.
Trial Met Primary Composite Endpoint of Reduction in Heart Failure Events Or Cardiovascular Death.
Galactic-hf Trial Did Not Meet Secondary Endpoints Including Reduction in Cardiovascular Death.
Overall Safety Profile of Omecamtiv Mecarbil in Galactic-hf Appears to Be Consistent With Data From Previous Trials.
Revenue is expected to be $23.76 Million
Adjusted EPS is expected to be -$0.43

Next Quarter Revenue Guidance is expected to be $29.44 Million
Next Quarter EPS Guidance is expected to be -$0.16

More details on our Analysts Page.